A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.

Driving business growth through innovative food and nutrition strategies for CPG & foodservice brands. 💡 The Rise of GLP-1 ...

Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

Novo Nordisk’s blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday, as the Asian nation battles ...